

Barbara Spitzer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7948550/publications.pdf>

Version: 2024-02-01

34
papers

2,272
citations

567281

15
h-index

501196

28
g-index

34
all docs

34
docs citations

34
times ranked

5015
citing authors

#	ARTICLE	IF	CITATIONS
1	Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2022, 6, 1054-1063.	5.2	12
2	Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 1614-1627.	7.0	4
3	Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis. <i>Nature Communications</i> , 2021, 12, 338.	12.8	64
4	ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML. <i>Blood Advances</i> , 2021, 5, 1899-1902.	5.2	8
5	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. <i>Nature Genetics</i> , 2020, 52, 1219-1226.	21.4	367
6	Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation. <i>Cytotherapy</i> , 2020, 22, 503-510.	0.7	27
7	Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 2160-2169.	2.4	11
8	Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. <i>Journal of Clinical Investigation</i> , 2020, 130, 733-747.	8.2	161
9	Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access. <i>Blood</i> , 2020, 136, 23-24.	1.4	3
10	Interplay between Chromosomal Alterations and Gene Mutations Shapes the Evolutionary Trajectory of Clonal Hematopoiesis. <i>Blood</i> , 2020, 136, 29-30.	1.4	0
11	Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults. <i>Blood</i> , 2020, 136, 30-31.	1.4	0
12	Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. <i>Blood</i> , 2019, 134, 2361-2368.	1.4	190
13	De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes. <i>Blood</i> , 2019, 134, 2708-2708.	1.4	2
14	Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL. <i>Blood</i> , 2019, 134, 4582-4582.	1.4	0
15	MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2018, 8, 478-497.	9.4	59
16	De Novo Skin Xerosis in Cord Blood Transplantation is Associated with Distinct Histopathology and Treatment Response: First Literature Report of Cord Dermatitis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S193-S194.	2.0	1
17	JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. <i>Journal of Clinical Investigation</i> , 2018, 128, 789-804.	8.2	66
18	AML with Mutations in IDH1 and DNMT3A Exhibits a Distinct Epigenetic Signature with Poorer Overall Survival. <i>Blood</i> , 2018, 132, 1471-1471.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Early Detection and Molecular Characterization of Therapy-Related Leukemia in Children Reveals Patterns of Disease Transformation and Guides Future Surveillance Protocols. <i>Blood</i> , 2018, 132, 291-291.	1.4	0
20	A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2088-2095.	2.0	9
21	Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1449-1454.	2.0	8
22	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. <i>Nature Medicine</i> , 2016, 22, 1488-1495.	30.7	195
23	Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". <i>Nature Medicine</i> , 2016, 22, 578-579.	30.7	7
24	Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. <i>Nature</i> , 2016, 531, 471-475.	27.8	202
25	Acid ceramidase is upregulated in AML and represents a novel therapeutic target. <i>Oncotarget</i> , 2016, 7, 83208-83222.	1.8	73
26	Late complications of mixed chimerism following allogeneic bone marrow transplantation for thalassemia major. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1303-1304.	1.5	5
27	Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2015, 5, 16.	2.8	24
28	CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. <i>Cancer Cell</i> , 2015, 28, 15-28.	16.8	124
29	Loss of BAP1 function leads to EZH2-dependent transformation. <i>Nature Medicine</i> , 2015, 21, 1344-1349.	30.7	297
30	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. <i>Journal of Experimental Medicine</i> , 2015, 212, 1819-1832.	8.5	137
31	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. <i>Journal of Cell Biology</i> , 2015, 211, 2111OIA226.	5.2	0
32	Dose-Dependent Role of the Cohesin Complex in Normal and Malignant Hematopoiesis. <i>Blood</i> , 2015, 126, 435-435.	1.4	1
33	Genetic alterations of the cohesin complex genes in myeloid malignancies. <i>Blood</i> , 2014, 124, 1790-1798.	1.4	204
34	Posttransplant Lymphoproliferative Disorder Complicating Hematopoietic Stem Cell Transplantation in a Patient With Dyskeratosis Congenita. <i>International Journal of Surgical Pathology</i> , 2013, 21, 520-525.	0.8	9